Dose-sparing effect of lapatinib co-administered with a high-fat enteral nutrition emulsion: preclinical pharmacokinetic study

BACKGROUND: Lapatinib is an oral small-molecule tyrosine kinase inhibitor indicated for advanced or metastatic HER2-positive breast cancer. In order to reduce the treatment cost, a high-fat enteral nutrition emulsion TPF-T was selected as a dose-sparing agent for lapatinib-based therapies. This stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Junfeng, Xu, Gaoqi, Yang, Dihong, Song, Yu, Tong, Yinghui, Kong, Sisi, Ding, Haiying, Fang, Luo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2023
Materias:
Drugs and Devices
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10569162/
https://www.ncbi.nlm.nih.gov/pubmed/37842056
http://dx.doi.org/10.7717/peerj.16207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10569162/
https://www.ncbi.nlm.nih.gov/pubmed/37842056
http://dx.doi.org/10.7717/peerj.16207

Ejemplares similares